# Padlock Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/padlock-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Cambridge, US
- Website: www.padlocktherapeutics.com
- Total disclosed funding: $23M
- Latest round: Series A (Dec 18, 2014)
- Investors on record: 2

## About

Padlock Therapeutics is a biopharmaceutical company focused on creating innovative treatments for autoimmune diseases. Its mission is to develop therapies that effectively modulate the immune response, targeting conditions like rheumatoid arthritis and lupus.Founded in 2014 and headquartered in Cambridge, US, Padlock Therapeutics specializes in biopharmaceuticals for autoimmune diseases. The company has been involved in 4 deals, with its most recent being a TRADE SALE to Bristol-Myers Squibb on March 23, 2016, for USD 225.00 mn, completing in April 2016. The founder’s history is not available.Padlock Therapeutics specializes in the development of innovative biopharmaceutical products aimed at addressing autoimmune diseases. The company's core offerings include proprietary drugs designed to modulate the immune system, thereby preventing or treating conditions such as rheumatoid arthritis and lupus. These products utilize advanced therapeutic techniques, potentially including small molecule inhibitors and biologics, which are targeted to provide precision treatment to patients. Padlock Therapeutics primarily serves healthcare providers and institutions, aiming to enhance the quality of life for patients suffering from chronic immune-related disorders. The company has established market presence in North America and parts of Europe, targeting both specialist clinics and larger healthcare networks that focus on chronic disease management.Padlock Therapeutics generates revenue through a combination of direct sales and strategic partnerships with healthcare institutions and pharmaceutical distributors. The company structures its transactions primarily through B2B relationships, where products are sold to hospitals and clinics that then administer these treatments to patients. Revenue streams are bolstered by ongoing collaborations with pharmaceutical companies for joint development and marketing efforts. Specific pricing plans for their flagship drug offerings are structured around both individual unit sales and bundled treatment packages, catering to the diverse needs of their client base. This pricing strategy aligns with industry standards, ensuring accessibility for healthcare providers while maintaining product value in a competitive market.Padlock Therapeutics is focusing on expanding its product line and geographic reach. The company aims to launch new therapies designed to target additional autoimmune conditions within the next few years. Recent funding from the TRADE SALE will support these initiatives, facilitating entry into new markets in Europe and Asia by 2024. The acquisition by Bristol-Myers Squibb is expected to enhance Padlock's operational capabilities and market access.

## Funding rounds

- Series A, Dec 18, 2014, $23M — Atlas Venture
- Series A, Jun 19, 2014 — Johnson & Johnson Innovation

## Investors

- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series A
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A